379 related articles for article (PubMed ID: 23369223)
1. Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.
Karahoca M; Momparler RL
Clin Epigenetics; 2013 Feb; 5(1):3. PubMed ID: 23369223
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
Momparler RL; Côté S; Eliopoulos N
Leukemia; 1997 Feb; 11(2):175-80. PubMed ID: 9009076
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of 5-Aza-2'-deoxycytidine (decitabine).
Momparler RL
Semin Hematol; 2005 Jul; 42(3 Suppl 2):S9-16. PubMed ID: 16015507
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine).
Momparler RL
Semin Oncol; 2005 Oct; 32(5):443-51. PubMed ID: 16210084
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation.
Momparler RL; Côté S; Momparler LF; Idaghdour Y
Clin Epigenetics; 2014; 6(1):19. PubMed ID: 25313314
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia.
Lemaire M; Momparler LF; Bernstein ML; Marquez VE; Momparler RL
Anticancer Drugs; 2005 Mar; 16(3):301-8. PubMed ID: 15711182
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
Momparler RL; Côté S; Eliopoulos N
Leukemia; 1997 Mar; 11 Suppl 1():S1-6. PubMed ID: 9130684
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of DNA and Histone Methylation by 5-Aza-2'-Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells.
Momparler RL; Côté S; Momparler LF; Idaghdour Y
Front Oncol; 2017; 7():19. PubMed ID: 28261562
[TBL] [Abstract][Full Text] [Related]
9. A Perspective on the Comparative Antileukemic Activity of 5-Aza-2'-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza).
Momparler RL
Pharmaceuticals (Basel); 2012 Aug; 5(8):875-81. PubMed ID: 24280679
[TBL] [Abstract][Full Text] [Related]
10. Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms.
Schmelz K; Sattler N; Wagner M; Lübbert M; Dörken B; Tamm I
Leukemia; 2005 Jan; 19(1):103-11. PubMed ID: 15510208
[TBL] [Abstract][Full Text] [Related]
11. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells.
Hurtubise A; Momparler RL
Cancer Chemother Pharmacol; 2006 Nov; 58(5):618-25. PubMed ID: 16783580
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine.
Lemaire M; Momparler LF; Raynal NJ; Bernstein ML; Momparler RL
Cancer Chemother Pharmacol; 2009 Feb; 63(3):411-6. PubMed ID: 18398609
[TBL] [Abstract][Full Text] [Related]
13. Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer.
Momparler RL; Bouffard DY; Momparler LF; Dionne J; Belanger K; Ayoub J
Anticancer Drugs; 1997 Apr; 8(4):358-68. PubMed ID: 9180389
[TBL] [Abstract][Full Text] [Related]
14. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer.
Lemaire M; Chabot GG; Raynal NJ; Momparler LF; Hurtubise A; Bernstein ML; Momparler RL
BMC Cancer; 2008 May; 8():128. PubMed ID: 18454857
[TBL] [Abstract][Full Text] [Related]
15. 3-Deazauridine enhances the antileukemic action of 5-aza-2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase.
Raynal NJ; Momparler LF; Rivard GE; Momparler RL
Leuk Res; 2011 Jan; 35(1):110-8. PubMed ID: 20510451
[TBL] [Abstract][Full Text] [Related]
16. GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells.
Chiam K; Centenera MM; Butler LM; Tilley WD; Bianco-Miotto T
PLoS One; 2011; 6(9):e25634. PubMed ID: 21980513
[TBL] [Abstract][Full Text] [Related]
17. S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth.
Chuang JC; Warner SL; Vollmer D; Vankayalapati H; Redkar S; Bearss DJ; Qiu X; Yoo CB; Jones PA
Mol Cancer Ther; 2010 May; 9(5):1443-50. PubMed ID: 20442312
[TBL] [Abstract][Full Text] [Related]
18. Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides.
Yoo CB; Jeong S; Egger G; Liang G; Phiasivongsa P; Tang C; Redkar S; Jones PA
Cancer Res; 2007 Jul; 67(13):6400-8. PubMed ID: 17616700
[TBL] [Abstract][Full Text] [Related]
19. Interaction of 5-aza-2'-deoxycytidine with amsacrine or 1,25-dihydroxyvitamin D3 on HL-60 myeloid leukemic cells and inhibitors of cytidine deaminase.
Momparler RL; Doré BT; Labiberté J; Momparler LF
Leukemia; 1993 May; 7 Suppl 1():17-20. PubMed ID: 7683351
[TBL] [Abstract][Full Text] [Related]
20. Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycytidine.
Momparler RL; Laliberté J
Leuk Res; 1990; 14(9):751-4. PubMed ID: 1700230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]